<DOC>
	<DOCNO>NCT01507103</DOCNO>
	<brief_summary>The objective mechanistic study determine impact tecemotide ( L-BLP25 ) administration mucinous glycoprotein 1 - ( MUC1 ) specific immune response subject newly diagnose rectal cancer eligible neoadjuvant therapy . Tecemotide ( L-BLP25 ) design induce immune response may lead immune rejection tumor tissue aberrantly express MUC1 antigen . MUC1 highly express colorectal cancer since adaptive immune system play role prognosis rectal cancer , reasonable speculate tecemotide ( L-BLP25 ) administration might boost tumor-specific immune response increase number tumor-infiltrating lymphocyte ( TILs ) .</brief_summary>
	<brief_title>Tecemotide ( L-BLP25 ) Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Male female subject histologically document resectable rectal adenocarcinoma Stage 24 2 . Availability tumor biopsy sufficient immunological analysis 3 . Indication receive neoadjuvant concomitant chemoradiotherapy consist radiation dose 4552 Gy capecitabine 825 mg/m^2 orally twice daily . The use equivalent schedule base 5FU acceptable 4 . Magnetic resonance image small pelvis / compute tomography thorax/abdomen ( Xray thorax ) document absence metastatic disease . Imaging must older 6 week prior randomization 5 . Eastern Cooperative Oncology Group performance status 0 1 6 . Written inform consent 7 . Greater equal ( &gt; = ) 18 year age 1 . Previous chemotherapy and/or previous radiotherapy pelvic region 2 . Relapsing disease 3 . Previous vaccination MUC1 vaccine therapeutic cancer vaccine 4 . Previous organ transplantation ( bone marrow solid organ ) 5 . Subjects metastatic disease ( except solitary , resectable liver lung metastasis ) 6 . Inadequate hematological function ( , platelet count le 140*10^9 per liter [ /L ] , white blood cell less 2.5*10^9/L , hemoglobin le 90 gram per liter ) . Clinically significant hepatic dysfunction ( alanine aminotransferase great 2.5*upper limit normal [ ULN ] , aspartate aminotransferase great 2.5*ULN , bilirubin great 1.5*ULN ) . Inadequate renal function ( serum creatinine great 1.5*ULN ) 7 . Autoimmune diseases 8 . Recognized immunodeficiency disease include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia ; subject hereditary congenital immunodeficiency 9 . Clinically significant cardiac disease , example , New York Heart Association Classes IIIIV ; uncontrolled angina , uncontrolled arrhythmia uncontrolled hypertension , myocardial infarction previous 6 month confirm medical history electrocardiogram 10 . Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tecemotide ( L-BLP25 )</keyword>
	<keyword>Cyclophosphamide ( CPA )</keyword>
	<keyword>Mode action</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Carcinomas</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Radiotherapy Pharmacologic Actions</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Immunologic Function</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>